Relay Therapeutics CFO sells 17,717 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock in open-market transactions on July 6, 2026 at a weighted average price of $18.69 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025, meaning the sales were scheduled in advance.
The sale was completed in multiple trades at prices ranging from $18.39 to $19.38 per share. After these transactions, Catinazzo directly owns 159,744 shares of Relay Therapeutics common stock, which includes 9,807 shares underlying restricted stock units.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 17,717 | $18.69 | $331K |
Footnotes (3)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $18.39 to $19.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. Includes 9,807 shares underlying restricted stock units.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
restricted stock units financial
open-market sale financial
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Relay Therapeutics (RLAY) disclose for its CFO?
Was the Relay Therapeutics (RLAY) CFO’s stock sale pre-planned?
What type of security did the Relay Therapeutics (RLAY) CFO sell?
Does the Relay Therapeutics (RLAY) Form 4 mention restricted stock units for the CFO?
AI-generated analysis. How Rhea-AI works. Not financial advice.